ADHD薬剤療法とADHD患者の死亡率
Lin Li1, Nanbo Zhu1, Le Zhang1
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
JAMA
|March 12, 2024
まとめ
スウェーデンでは,注意欠陥/多動性障害 (ADHD) の治療薬の投与は,2年以内に全因死亡率の有意な減少と関連していました. このADHDの薬剤療法の利点は,非自然死において特に顕著でした.
科学分野:
- 精神科
- 公衆衛生
- 薬理学について
背景:
- 注意欠陥/多動性障害 (ADHD) は死亡リスクの増加と関連しています.
- 死亡リスクに対するADHDの薬剤療法の影響は不明である.
研究 の 目的:
- ADHDの薬剤療法を開始すると,ADHDと診断された個人の死亡リスクが低下するかどうかを調査する.
主な方法:
- スウェーデンにおけるターゲット試験エミュレーションフレームワークを用いた全国的な観察コホート研究.
- 6歳から64歳のADHD診断 (2007年−2018年) を受けた人,以前の薬物治療を受けていない人.
- 診断から2年以内に全原因,自然原因,非自然原因による死亡率を評価した.
主要な成果:
- ADHDの148,578人のうち56.7%が治療を開始しました
- 薬の投与開始は,あらゆる原因による死亡率の有意な低下と関連していた (HR,0. 79).
- 治療開始は非自然死 (HR,0. 75) を有意に減少させたが,自然死は減少しなかった.
結論:
- 全ての原因による死亡率を 大幅に低下させています
- 死亡率の減少は,非自然原因による死亡において特に顕著です.
- 発見はADHDの薬物療法による 潜在的な死亡率の利点を示唆しています
さらに関連する動画
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.3K
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.7K
関連する概念動画
Attention-Deficit/Hyperactivity Disorder
67
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
67
Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Adrenergic Agonists: Therapeutic Uses
774
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
774
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Psychosis: Goals of Pharmacotherapy
128
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
128
